Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C

Figure 1 Duration of interferon-β (IFN-β) therapy and peginterferon-α (Peg-IFN-α) plus ribavirin (RBV) combination therapy, and the numbers of patients.

Figure 2 The SVR rate and 95% confidence interval (95% CI) by dosing duration of peginterferon (Peg-IFN) plus ribavirin (RBV) after interferon-β induction therapy. The significance of the difference was evaluated employing Fisher’s exact test.

Figure 3 The SVR rate (%, n) by the baseline platelet count in patients whose HCV-RNA level decreased to below 3. 3 Log IU/mL at the end of interferon-β treatment. Higher PLT indicates a platelet (PLT) count of ≥ 130 000/mL at the start of therapy. The significance of the difference was evaluated using Fisher’s exact test. Peg-IFN: Peginterferon; RBV: Ribavirin.